Moreover, we demonstrate that VEGF-targeting treatments, when applied as monotherapy, can increase tumor hypoxia and cell spread, a finding clearly in line with the proposed selection of more hypoxia tolerant and metastasis-prone malignant clonal variants in response to Avastin®- or Sunitinib®-related interventions. This evidence concerns the gene VEGFA and neoplasm.